MedTrace Logo

Associations Between General Movements Assessments and Cognitive Development

NCT05217056 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2022-02-01

No results posted yet for this study

Summary

High risk infant is defined as infant with a negative history of environmental and biological factors, which can lead to neuromotor development problems. It is a heterogeneous group of premature infants born under thirty-seven weeks of age, with infants with low birth weight, term or developmental retardation for various reasons. Therefore, preterm infants with low birth weight can survive with a neurological sequelae such as cerebral palsy (CP), epilepsy, hearing and vision loss, mental retardation, speech and speech problems, and learning difficulties. The clinical diagnosis of CP and learning diffuculties which can be observed in high-risk infants, is based on the combination of some neurological and clinical signs.

Conditions

  • Cerebral Palsy
  • Infant Development
  • Cognitive Dysfunction
  • Cognitive Developmental Delay
  • Cognitive Impairment, Mild
  • Infant, Small for Gestational Age
  • Infant, Premature, Diseases
  • Infant Asphyxia
  • Infant, Very Low Birth Weight

Interventions

OTHER

measurements

All of the infants with high risk of cerebral palsy will be assessed from birth to 12 months age with the assessments of Prechtl's General movements (GMs) until 20 weeks of age. Also BAYLEY-III Infant and Toddler Development Assessment Scale (BAYLEY-III) will be performed at the 3rd, 6th, and 12th months for the cognitive development.

Sponsors & Collaborators

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Principal Investigators

  • hatice adıgüzel, PhD · Kahramanmaras Sutcu Imam University

  • Bulent Elbasan, Proffessor · Gazi University

Eligibility

Min Age
25 Weeks
Max Age
42 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-08-30
Completion
2021-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05217056 on ClinicalTrials.gov